Pharmacokinetic Interaction of Favipiravir with Citalopram and Pioglitazone

The current study's objective was to investigate the interactions of favipiravir with pioglitazone and citalopram. 25 Spraque-Dawley female rats were used in study. Rats groups 1 4 given (1 mg/kg/day) for 7 days 2 5 citalopram (1.5 days. 3, 4, a loading dose (50 mg/kg) on 6th day study maintenance (30 7th After last drug administration, blood samples taken from at 15, 30, 45 minutes, 1, 2, 6, 8 hours. Plasma concentrations drugs determined by high-performance liquid chromatography (HPLC). aldehyde oxidase (AO) xanthine (XO) activities liver tissues enzyme-linked immunosorbent assay (ELISA). Pioglitazone changed pharmacokinetics increased t1/2, AUC, MRT Cl values. Favipiravir did not affect steady state. When together, significantly decreased while increasing citalopram's While Cmax, AUMC, values favipiravir, it decreasing AUC value. Pharmacokinetic have been between AO substrates or modulators. It is thought that if results obtained are supported human studies, will guide concomitant use these clinic prevent occurrence adverse reactions. Keywords: Drug-drug interaction, Favipiravir, Pioglitazone, Citalopram, Aldehyde